The reduction in price target by B. Riley Securities could have a mixed impact on Actinium Pharma's stock price. While maintaining a Buy rating is positive, lowering the price target may signal a tempered but still optimistic outlook on the company's valuation, which could lead to a neutral short-term impact on the stock as investors digest the news.